MLTX MoonLake Immunotherapeutics: institutional ownership and insider trading
186 funds reported holding $1.56B of MoonLake Immunotherapeutics in their latest 13F filings; in Q2 2026 funds net bought $205M, with 40 new positions and 15 funds selling out; over the last 12 months insiders bought $0 and sold $83.0M on the open market.
MLTX revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$61.8M, EPS -0.84
- Quarter ended Mar 31, 2026: revenue n/a, net income −$69.7M, EPS -0.98
- Quarter ended Dec 31, 2025: revenue n/a, net income −$62.4M, EPS -0.93
- Quarter ended Sep 30, 2025: revenue n/a, net income −$69.7M, EPS -1.10
Famous investors holding MLTX
- D. E. Shaw (D. E. Shaw & Co.): $65.5M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $33.4M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $12.5M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $47.9M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $12.4M, 0.0% of the portfolio
Largest institutional holders of MLTX
- BVF INC/IL — $312M
- Deep Track Capital, LP — $136M
- T. Rowe Price Investment Management, Inc. — $83.3M
- D. E. Shaw & Co., Inc. — $65.5M
- JANUS HENDERSON GROUP PLC (JHG) — $64.3M
- Cormorant Asset Management, LP — $62.4M
- Jupiter Topco LLC — $60.1M
- Logos Global Management LP — $52.1M
- Weiss Asset Management LP — $50.3M
- CITADEL ADVISORS LLC — $47.9M
Recent MLTX insider trades
- Jul 27, 2026: Reich Kristian sold 1,100 shares ($22.0K)
- Jul 22, 2026: Reich Kristian sold 52,448 shares ($1.05M)
- Jul 20, 2026: Reich Kristian sold 43,700 shares ($878K)
- Jul 15, 2026: Reich Kristian sold 16,105 shares ($322K)
5%+ owners
- BVF PARTNERS L P/IL: 19.7% (Schedule 13D/A, filed Jun 29, 2026)
- Deep Track Capital, LP: 9.7% (Schedule 13G/A, filed Aug 14, 2026)
- T. Rowe Price Investment Management, Inc.: 5.3% (Schedule 13G, filed Aug 14, 2026)
Who owns the most MLTX stock?
The largest institutional holders of MoonLake Immunotherapeutics in the latest 13F filings are BVF INC/IL ($312M), Deep Track Capital, LP ($136M), T. Rowe Price Investment Management, Inc. ($83.3M).
Are insiders buying or selling MLTX?
Over the last 12 months insiders bought $0 and sold $83.0M of MoonLake Immunotherapeutics stock on the open market (SEC Form 4).
Which famous investors own MLTX?
D. E. Shaw, Two Sigma, Renaissance Technologies, Ken Griffin, Izzy Englander.
Which ETFs hold MLTX?
5 ETFs and mutual funds hold it among their top 100 positions, including TCAF, DLHAX, SBIO, BBC.